ACQUISITION, Part IV (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended			6 Months Ended			12 Months Ended	18 Months Ended
	Jun. 25, 2012	Jun. 30, 2012	Jun. 30, 2011	Jun. 25, 2012	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Jun. 30, 2012
Unaudited pro forma financial information [Abstract]
Revenues		$ 83,385	$ 82,380		$ 167,396	$ 173,913
Net income (loss)		(9,578)	(18,584)		(19,038)	25,700
Business Acquisition, Pro Forma Earnings Per Share, Basic		$ (0.14)	$ (0.27)		$ (0.27)	$ 0.36
Business Acquisition, Pro Forma Earnings Per Share, Diluted		$ (0.14)	$ (0.27)		$ (0.27)	$ 0.32
Business Acquisition, Cost of Acquired Entity, Acceleration of Stock Options	8,265			8,265
Income tax (benefit) provision related to acquisition		(44,704)			(44,704)
Business Acquisition, Cost of Acquired Entity, Transaction Costs Duration	4,710	4,710		5,766	5,766		2,936	8,702
Business Acquisition, Cost of Acquired Entity, Transaction Costs incurred by eBioscience		$ 5,338			$ 5,470